CY1116176T1 - 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν - Google Patents
2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουνInfo
- Publication number
- CY1116176T1 CY1116176T1 CY20151100336T CY151100336T CY1116176T1 CY 1116176 T1 CY1116176 T1 CY 1116176T1 CY 20151100336 T CY20151100336 T CY 20151100336T CY 151100336 T CY151100336 T CY 151100336T CY 1116176 T1 CY1116176 T1 CY 1116176T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aryl
- derivatives
- pharmaceutical compositions
- compositions containing
- propionic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164605A EP2166006A1 (en) | 2008-09-18 | 2008-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| EP09783167.1A EP2346841B1 (en) | 2008-09-18 | 2009-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116176T1 true CY1116176T1 (el) | 2017-02-08 |
Family
ID=40291117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100336T CY1116176T1 (el) | 2008-09-18 | 2015-04-08 | 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8624036B2 (https=) |
| EP (2) | EP2166006A1 (https=) |
| JP (1) | JP5571669B2 (https=) |
| CN (1) | CN102159558B (https=) |
| AU (1) | AU2009294558B2 (https=) |
| CA (1) | CA2737099C (https=) |
| CY (1) | CY1116176T1 (https=) |
| DK (1) | DK2346841T3 (https=) |
| ES (1) | ES2534634T3 (https=) |
| HR (1) | HRP20150395T1 (https=) |
| IL (1) | IL211683A (https=) |
| PL (1) | PL2346841T3 (https=) |
| PT (1) | PT2346841E (https=) |
| RU (1) | RU2520212C2 (https=) |
| SI (1) | SI2346841T1 (https=) |
| SM (1) | SMT201500098B (https=) |
| WO (1) | WO2010031835A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2634185T3 (en) | 2012-03-02 | 2016-03-21 | Sareum Ltd | Tyk2 kinase inhibitors |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| RU2652795C2 (ru) * | 2013-09-03 | 2018-05-03 | Сареум Лимитед | Производные 2-фенил-оксазол-4-карбоксамида, модулирующие активность jak и tyk2 киназ |
| AR103399A1 (es) * | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| EP3117835A1 (en) | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment of certain urological disorders |
| EP3192504A1 (en) | 2016-01-15 | 2017-07-19 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| WO2017121838A1 (en) * | 2016-01-15 | 2017-07-20 | Dompe' Farmaceutici S.P.A. | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| US11291641B2 (en) | 2016-10-03 | 2022-04-05 | The Children's Medical Center Corporation | Prevention and treatment of diabetic nephropathy |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
| EP3409277A1 (en) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections |
| EP3476390A1 (en) * | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| EP3868369A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue |
| EP3868368A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| EP4008325A1 (en) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3884932A1 (en) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP4125848A1 (en) | 2020-03-26 | 2023-02-08 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of covid-19 |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
| IL302553A (en) | 2020-11-05 | 2023-07-01 | Icahn School Med Mount Sinai | Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis |
| EP4052702A1 (en) | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures |
| EP4397305A1 (en) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
| EP4406942A1 (en) * | 2023-01-26 | 2024-07-31 | Dompe' Farmaceutici S.P.A. | Stable monohydrate of df2755a and process for its preparation |
| EP4563594A1 (en) | 2023-11-28 | 2025-06-04 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels |
| EP4678171A1 (en) | 2024-07-10 | 2026-01-14 | Dompé farmaceutici SpA | Systemically-administered cxcl8 inhibitors for use in the prevention or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
| EP4686469A1 (en) | 2024-07-31 | 2026-02-04 | Dompé farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities |
| EP4686472A1 (en) | 2024-08-02 | 2026-02-04 | Dompé farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of ocular graft-versus-host disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4025528A (en) * | 1973-10-24 | 1977-05-24 | Shionogi & Co., Ltd. | Thiazole derivatives of benzoic and phenylalkanoic acids |
| CA1051906A (en) * | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Thiazole derivatives and production thereof |
| JPS5537556B2 (https=) * | 1973-12-27 | 1980-09-29 | ||
| JPS565747B2 (https=) * | 1973-10-24 | 1981-02-06 | ||
| JPS5629871B2 (https=) * | 1974-05-22 | 1981-07-10 | ||
| JPS62142168A (ja) * | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| IT1298214B1 (it) | 1998-01-28 | 1999-12-20 | Dompe Spa | Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche. |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| IT1317826B1 (it) | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| EP1467981A1 (en) * | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| ATE444286T1 (de) * | 2004-03-23 | 2009-10-15 | Dompe Pha R Ma Spa Res & Mfg | 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung |
| RU2458051C2 (ru) * | 2005-11-24 | 2012-08-10 | ДОМПЕ ФА.Р.МА С.п.А. | (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции |
| PT2024329E (pt) * | 2006-05-18 | 2013-11-04 | Dompe Spa | (2r)-2-[(4-sulfonil)aminofenil]propanamidas e composições farmacêuticas que as contenham |
| PT2094638E (pt) * | 2006-12-19 | 2012-11-20 | Dompe Spa | Ácidos 2-aril-fluoropropanóicos e derivados e composições farmacêuticas que os contêm |
| PT2201006E (pt) * | 2007-10-18 | 2011-05-05 | Domp S P A | Derivados de (r)-4-(heteroaril)-feniletilo e composi??es farmac?uticas que os cont?m |
-
2008
- 2008-09-18 EP EP08164605A patent/EP2166006A1/en not_active Withdrawn
-
2009
- 2009-09-18 WO PCT/EP2009/062109 patent/WO2010031835A2/en not_active Ceased
- 2009-09-18 CA CA2737099A patent/CA2737099C/en active Active
- 2009-09-18 US US13/063,105 patent/US8624036B2/en active Active
- 2009-09-18 SI SI200931170T patent/SI2346841T1/sl unknown
- 2009-09-18 ES ES09783167.1T patent/ES2534634T3/es active Active
- 2009-09-18 RU RU2011114992/04A patent/RU2520212C2/ru active
- 2009-09-18 PL PL09783167T patent/PL2346841T3/pl unknown
- 2009-09-18 DK DK09783167.1T patent/DK2346841T3/en active
- 2009-09-18 AU AU2009294558A patent/AU2009294558B2/en active Active
- 2009-09-18 CN CN200980136860.5A patent/CN102159558B/zh active Active
- 2009-09-18 PT PT97831671T patent/PT2346841E/pt unknown
- 2009-09-18 EP EP09783167.1A patent/EP2346841B1/en active Active
- 2009-09-18 JP JP2011527334A patent/JP5571669B2/ja active Active
- 2009-09-18 HR HRP20150395TT patent/HRP20150395T1/hr unknown
-
2011
- 2011-03-10 IL IL211683A patent/IL211683A/en active IP Right Grant
-
2015
- 2015-04-08 CY CY20151100336T patent/CY1116176T1/el unknown
- 2015-04-22 SM SM201500098T patent/SMT201500098B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2346841A2 (en) | 2011-07-27 |
| US20110207785A1 (en) | 2011-08-25 |
| EP2346841B1 (en) | 2015-01-14 |
| CN102159558A (zh) | 2011-08-17 |
| IL211683A0 (en) | 2011-06-30 |
| JP2012502957A (ja) | 2012-02-02 |
| CA2737099A1 (en) | 2010-03-25 |
| IL211683A (en) | 2014-01-30 |
| WO2010031835A2 (en) | 2010-03-25 |
| AU2009294558B2 (en) | 2014-12-18 |
| ES2534634T3 (es) | 2015-04-27 |
| EP2166006A1 (en) | 2010-03-24 |
| CN102159558B (zh) | 2015-01-07 |
| BRPI0918759A2 (pt) | 2015-12-29 |
| RU2011114992A (ru) | 2012-10-27 |
| SI2346841T1 (sl) | 2015-07-31 |
| PT2346841E (pt) | 2015-05-07 |
| US8624036B2 (en) | 2014-01-07 |
| DK2346841T3 (en) | 2015-04-20 |
| RU2520212C2 (ru) | 2014-06-20 |
| WO2010031835A3 (en) | 2010-06-24 |
| JP5571669B2 (ja) | 2014-08-13 |
| PL2346841T3 (pl) | 2015-07-31 |
| AU2009294558A1 (en) | 2010-03-25 |
| HRP20150395T1 (hr) | 2015-06-19 |
| SMT201500098B (it) | 2015-07-09 |
| CA2737099C (en) | 2016-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116176T1 (el) | 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν | |
| CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
| CY1118909T1 (el) | Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων | |
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| MX383804B (es) | Derivados de piperidina. | |
| EA201201663A1 (ru) | Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1 | |
| MX381953B (es) | Sales de derivados de piperazina obtenidas por adicion de acidos. | |
| MX2020002924A (es) | Lactamas fusionadas de arilo y heteroarilo. | |
| CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
| CY1117934T1 (el) | Αντιβακτηριακες φαρμακευτικες συνθεσεις | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| EA201101026A1 (ru) | Ингибиторы бета-секретазы | |
| MA32442B1 (fr) | Inhibiteurs de la syk protéine kinase | |
| MX386166B (es) | Derivados de piperidina 1,4-sustituidos. | |
| CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| CY1108529T1 (el) | Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| CY1116548T1 (el) | Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| WO2012138955A3 (en) | CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS | |
| HK1231471A1 (zh) | 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途 | |
| BR112013016595A2 (pt) | inibidores de neprilisina | |
| BRPI0914802B8 (pt) | composto heterocíclico, e, medicamento | |
| CY1120515T1 (el) | Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου | |
| JO3577B1 (ar) | صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt |